Roth Capital Weighs in on Fortress Biotech, Inc.’s Q3 2024 Earnings (NASDAQ:FBIO)

Fortress Biotech, Inc. (NASDAQ:FBIO – Free Report) – Roth Capital raised their Q3 2024 EPS estimates for shares of Fortress Biotech in a note issued to investors on Wednesday, August 14th. Roth Capital analyst J. Wittes now forecasts that the biopharmaceutical company will post earnings per share of ($0.27) for the quarter, up from their […]

Leave a Reply

Your email address will not be published.

Previous post Northland Capmk Analysts Raise Earnings Estimates for DURECT Co. (NASDAQ:DRRX)
Next post Jasper Therapeutics, Inc. (NASDAQ:JSPR) to Post Q3 2024 Earnings of ($1.02) Per Share, Capital One Financial Forecasts